IngredientsTynanthus elegans, known as cipó-cravo or cipó-trindade in Portuguese, is a species of flowering plant in the family Bignoniaceae. Its full taxonomic hierarchy places it in the kingdom Plantae, phylum Tracheophyta, class Magnoliopsida, order Lamiales, family Bignoniaceae, and genus Tynanthus. The genus Tynanthus was established by British botanist John Miers in 1863, based on specimens from tropical America. The name derives from the Greek words tynos (small or little) and anthos (flower), alluding to the diminutive size of the genus's flowers.
Within the family Bignoniaceae, Tynanthus is classified in the tribe Bignonieae, a diverse clade of Neotropical lianas comprising about 21 genera and approximately 390 species. Tynanthus is a monophyletic genus of lianas easily recognized by small bilabiate flowers, fruits with raised margins, and by the smell of cloves in vegetative organs.
Tynanthus elegans Miers carries the synonyms Bignonia elegans Cham. and Schizopsis regnelliana Bureau ex Baill. A critical taxonomic development occurred in the 2015 monographic revision of the genus: in the taxonomic revision by Medeiros and Lohmann (2015), Tynanthus elegans was synonymized with Tynanthus cognatus. The morphological similarity between Tynanthus cognatus and T. elegans had long been noted; indeed, Chamisso (1832) commented on their overall similarity when those taxa were originally described as Bignonia cognata and B. elegans, respectively. Chamisso also noted differences in the type and density of indumentum in the vegetative and reproductive organs; however, a detailed analysis showed that indumentum density varies geographically.
Certain older commercial and popular literature has treated Tynanthus elegans as a synonym for Tynanthus panurensis (the Amazonian "clavo huasca"), which is an error. Among all studied species in a 2015 chemical review, T. cognatus (Cham.) Miers and T. elegans Miers have related studies, although they do not mention their chemical composition and only refer to morphological and phytosociological aspects. The plant encountered in the supplement trade under the label "Tynanthus elegans" may therefore correspond to what current taxonomy recognizes as Tynanthus cognatus, and considerable care is warranted when interpreting historical literature that uses the older name.
Tynanthus elegans is found in Bolivia and Brazil. More specifically, T. elegans Miers is a native plant of Brazil, found in the southeastern states (Espírito Santo, Minas Gerais, Rio de Janeiro, and São Paulo) and southern states (Paraná, Rio Grande do Sul, and Santa Catarina).
Tynanthus cognatus (the currently accepted name for T. elegans) is a climbing shrub that attaches itself to other plants for support by means of tendrils. Species of Tynanthus are distributed throughout the Neotropics, occurring predominantly in wet forests. The highest diversity of Tynanthus is found in Brazil, with most species occurring in Amazonia and the Atlantic Forest.
The wood and leaves of this species have an aromatic odour similar to that of cloves (Syzygium aromaticum). This species was highlighted in a phytosociological survey of a liana community in a seasonal semideciduous forest in São Carlos, São Paulo, Brazil, which showed a prevalence of species from the Bignoniaceae, Malpighiaceae, Sapindaceae, and Apocynaceae families; T. elegans had the third highest importance value (IV), a parameter directly related to relative dominance in that region.
Common names and nomenclature associated with this species include:
The plant is harvested from the wild for local use as a medicine. In commerce and traditional preparation, plant parts used include stems, bark, leaves, and roots, typically presented as dried plant material for decoction or infusion, or prepared as an alcohol-based tincture or macerate.
The Brazilian Pharmacopoeia (Farmacopéia, 1929) describes T. fasciculatus and T. elegans as carminative plants, and Correa (1974) reports that the population uses these plants for aphrodisiac purposes, also citing their toxic effects. This represents one of the earliest formal documentary references to T. elegans in a regulatory pharmacopoeial context, situating its traditional use within an established Brazilian herbal medicine framework by at least the early twentieth century.
The use of T. elegans for supporting the gastrointestinal tract is primarily based on ethnobotanical records, where decoctions and infusions of the plant have been taken to alleviate digestive discomforts such as stomach aches and bloating. The aromatic properties of the plant, which resemble those of clove and cinnamon, have contributed to its traditional use as a carminative and digestive aid. The stem and root bark are described as carminative, stimulant, stomachic, and tonic; they also appear to be antidiarrheal and anthelmintic, with the stem especially used for treating conditions such as lack of appetite, poor digestion, and spasmodic and flatulent dyspepsia.
Traditionally, the stems and leaves of T. elegans have been prepared as teas or extracts believed to possess diuretic, anti-inflammatory, and aphrodisiac properties. Correa (1974) reports that the population uses these plants for aphrodisiac purposes. Brazilian folk use of closely related Tynanthus species as tonics and aphrodisiacs is additionally documented in the context of commercial folk remedies: another traditional product, Viriliflora®, was commercialized by the laboratory Flora Medicinal, and it was composed of tinctures of Ptychopetalum olacoides and Tynanthus fasciculatus (a closely related species to T. elegans).
Tynanthus elegans has a history of use in traditional South American medicine for a variety of ailments, including as a remedy to support recovery from injuries such as wounds, bruises, and inflammation. The plant is often used in folk medicine in the Amazon and Cerrado regions, with preparations typically involving decoctions or infusions of the bark or stems. Ethnobotanical surveys have documented its application for external and sometimes internal use, aimed at reducing swelling, pain, and facilitating the healing process.
Historically, indigenous peoples and local herbalists have used extracts and teas made from the stems and leaves of Tynanthus elegans to address respiratory ailments such as coughs, bronchitis, and other lung-related issues. The rationale for its use is primarily based on its aromatic properties and believed soothing effects on the respiratory tract. Ethnobotanical studies document its traditional use for "purifying the lungs" and as an expectorant.
Ethnobotanical surveys conducted in regions such as Brazil report its use by local populations for treating skin injuries, where preparations from its leaves or stems are applied topically. The rationale for this traditional use is often linked to the general belief in the medicinal properties of many liana species found in the Amazon and other tropical forests. Additionally, the juice from the inside of the fruit is applied to the eyes to treat conjunctivitis.
Among all studied species in the genus, T. cognatus (Cham.) Miers and T. elegans Miers have related studies, although they do not mention their chemical composition and only refer to morphological and phytosociological aspects. In other words, at the time of the most authoritative published review (Cansian et al., Brazilian Journal of Pharmaceutical Sciences, 2015), no dedicated phytochemical analysis of T. elegans specifically had been published. The compound data below are therefore drawn from: (a) preliminary, as-yet-limited analyses cited for T. elegans in secondary sources, and (b) the well-characterized genus-level chemistry — particularly from the closely related and now-synonymized T. cognatus and from the most-studied congener, T. panurensis.
Preliminary phytochemical analyses have identified the presence of bioactive compounds such as flavonoids, saponins, and essential oils, which are known for their antioxidant and anti-inflammatory potential. More specifically, phytochemical analyses of the bark of the most studied genus member, T. panurensis, have revealed a suite of compounds representative of the genus as a whole:
No mechanism studies have been published specifically for T. elegans. Mechanistic hypotheses are extrapolated from broader genus or compound-class data:
During the assessment of all the data incorporated in the primary 2015 genus review, it became possible to verify the deficiency of studies involving the majority of species of the genus Tynanthus. This finding applies with particular force to T. elegans specifically.
Evidence level: Preliminary; in vitro and indirect only.
The most directly applicable published study on antioxidant activity for the genus comes from T. micranthus. The aim of this study was to evaluate the potential in vitro antioxidant activity of Tynanthus micranthus and its activity on tyrosinase, a melanogenesis-involved enzyme. Methods employed included DPPH, phosphomolybdenum complex, catalase, peroxidase, superoxide dismutase (SOD), reduced glutathione (GSH), and mushroom tyrosinase activity assay. Results showed that the hydroalcoholic leaf fraction protected erythrocytes against oxidative stress and maintained normal levels of SOD and GSH, with an effect similar to catechin and quercetin used as standards. The leaf fraction also stimulated tyrosinase enzyme compared with the control, suggesting antioxidant potential and possible use in hypopigmentation diseases. For T. elegans itself, no equivalent study has been published. Robust clinical trials in humans are currently lacking, and much of the evidence for its efficacy is based on laboratory or animal studies.
Evidence level: Preliminary; in vitro only; no human studies.
The in vitro anti-inflammatory data that most closely informs T. elegans derives from a bark extract study of T. panurensis. The traditionally-used bark extract was studied for antioxidant and anti-inflammatory activities; phytochemical analysis showed the presence of saponins and a high concentration of phenols and flavonoids; in vitro tests revealed that the extract has free radical-scavenging antioxidant properties and reduces microsomal lipid peroxidation, uric acid synthesis, and tumor necrosis factor-α production. These are in vitro results in a related species and cannot be directly applied to T. elegans. There is a lack of robust scientific studies validating traditional uses specifically for treating injuries and inflammation.
Evidence level: Traditional documentation only; no controlled clinical or pharmacological studies.
Use for supporting the gastrointestinal tract is primarily based on ethnobotanical records, where decoctions and infusions of the plant have been taken to alleviate digestive discomforts such as stomach aches and bloating. The aromatic properties of the plant, which resemble those of clove and cinnamon, have contributed to its traditional use as a carminative and digestive aid. Scientific studies directly evaluating its efficacy or mechanism of action in gastrointestinal health are sparse; existing evidence consists mainly of anecdotal reports and historical documentation rather than controlled clinical trials or pharmacological studies.
Evidence level: Traditional and historical documentation; one related-species animal study; no human trials.
The aphrodisiac use of T. elegans is documented in Correa (1974) and the Brazilian Pharmacopoeia tradition. Animal-model evidence for aphrodisiac activity within the Tynanthus genus exists for a closely related species (T. micranthus); a 2014 study examined aphrodisiac properties in male mice. Some species of the genus Tynanthus have eugenol-rich essential oils. Despite evidence from related aromatic plants, no study has related the aphrodisiac activity of these Tynanthus species with the eugenol content. No human clinical trials on aphrodisiac endpoints using T. elegans have been published.
Evidence level: Preliminary; in vitro only.
Preliminary phytochemical analyses have identified the presence of bioactive compounds such as flavonoids, saponins, and essential oils, which are known for their antioxidant and anti-inflammatory potential. A few in vitro studies have demonstrated antimicrobial and antioxidant activities, suggesting possible health benefits. No controlled clinical antimicrobial trials have been conducted.
Evidence level: Traditional documentation only; no scientific validation.
Scientific validation of Tynanthus elegans for wound healing or for use on cuts is very limited. There are few, if any, peer-reviewed studies specifically investigating the plant's effects on wound healing, antimicrobial activity, or skin regeneration. Most of the available literature focuses on its phytochemistry or potential antioxidant properties, but not directly on its efficacy for treating skin injuries.
Evidence level: Traditional documentation and ethnobotanical recording only.
While there are a handful of studies exploring the plant's phytochemical profile — identifying compounds such as essential oils, saponins, and flavonoids — there is a lack of robust scientific studies such as controlled clinical trials or in-depth pharmacological assessments that directly validate its efficacy or mechanism of action in supporting the lungs. The justification for using Tynanthus elegans for lung health rests mainly on a foundation of traditional knowledge and anecdotal reports, rather than scientific validation.
Preparations in folk medicine in the Amazon and Cerrado regions typically involve decoctions or infusions of the bark or stems. Historically, Tynanthus elegans has been brewed as an herbal tea to address a variety of ailments. Traditionally, its stems and leaves have been prepared as teas or extracts believed to possess diuretic, anti-inflammatory, and aphrodisiac properties.
For closely related species sold in commerce (especially T. panurensis, which shares naming overlap in the supplement trade), the preparation most commonly cited for aphrodisiac use is an alcohol macerate: sections of the trunk and stems are macerated in aguardiente (sugar cane liquor), producing a drink said to be an aphrodisiac.
No standardized dosage for Tynanthus elegans specifically has been established in any peer-reviewed clinical study or pharmacopoeial monograph. The only dosage reference available in secondary literature — and pertaining to a commercially prepared extract of the related species T. panurensis — notes: traditional uses include use as a female aphrodisiac, for muscle pain, as a digestive aid, and as a male aphrodisiac; the suggested use cited is 30–60 drops 1–2 times daily of a 1:4 concentrated tincture extract. This reference is specific to the panurensis product and cannot be transposed to T. elegans without further study.
Correa (1974) reports that the population uses T. elegans for aphrodisiac purposes, also citing their toxic effects. The plant (as T. cognatus) is harvested from the wild for local use as a medicine; the plant has been suspected to be toxic, but there is no evidence available to prove or disprove this.
This analysis allowed appreciation of the deficiency of studies involving the toxicity of plants of the genus Tynanthus, a very important parameter when the subjects are plants routinely used by the population. Only T. fasciculatus and T. micranthus have been evaluated and showed a certain degree of toxicity against the microcrustacean Artemia salina, which may argue against the indiscriminate use of these plants. No equivalent toxicity study has been published for T. elegans.
No human safety data are available for T. elegans in pregnancy or breastfeeding. For the closely related and more studied genus member (T. panurensis): due to limited research, pregnant or breastfeeding women should avoid using the plant.
No formal drug interaction studies have been conducted for T. elegans. The constituent eugenol, present in genus members, is a known inhibitor of platelet aggregation and has interactions with anticoagulant medications documented for related plants, though this has not been formally studied for T. elegans preparations.
The deficiency of studies involving the toxicity of plants of the genus Tynanthus is a very important parameter, given that these are plants routinely used by the population. For T. elegans in particular, research into Tynanthus elegans is still emerging, and neither the therapeutic claims nor the safety profile have been adequately characterized by formal preclinical or clinical investigation.
The primary 2015 genus review aimed to gather information from published works concerning species of the genus Tynanthus and to detect flaws in research related to these plants, which may have great biological and pharmaceutical importance. The review points out some common chemical characteristics of these species, providing information that may help new researchers improve their knowledge about these plants.
The most pressing research gaps identified in the literature include:
Health conditions that Tynanthus elegans may help support.
Body systems that Tynanthus elegans may help support.
Go back